Fig. 7

Amplified FGFR1 promotes FGF2 induced cancer stemness through JAK-STAT pathway. A-B. Relative percentage changes of CSL cells/live cells (A) and relative percentage change of total mammosphere area for the 1st round culture (B) are shown in four ER + cell 3D cultures incubated with FGF2 (25ng/mL) plus PD166866 (1.0µM), TAS-120 (1.0µM), AZD1480 (0.2µM), SGC-CBP30 (10µM) and UC2288 (1.0µM). Cells from spheroids were incubated with FGF2 plus inhibitors for 72 h before ALDEFLUOR/CD44 staining or counting and replating for 1st round of mammosphere culture for 7 days. The DMSO treatments are used as controls and set as fold one. C-E. TCGA ER + breast cancer patients data analysis for interactions in the generalized linear model between FGF2 (X-axis):FGFR1 expression and their impact on ssGSEA pathways related to stemness (C-D) and JAK-STAT (E) (Y-axis, n = 601). The three linear fit curves and 95% C.I. (grey shaded area) are shown to indicate the interaction effects between FGF2 and FGFR1 expression, where FGFR1 expression levels were grouped by tertiles (high n = 206; low n = 199; med n = 196)